Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 314
- Registration Number
- NCT05468632
- Locations
- 🇲🇰
Novo Nordisk Investigational Site, Veles, North Macedonia
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 465
- Registration Number
- NCT05443334
- Locations
- 🇪🇸
Master Centre for Spain, Madrid, Spain
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 194
- Registration Number
- NCT05443568
- Locations
- 🇮🇱
Novo Nordisk Investigational Site, Kfar Saba, Israel
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
- Conditions
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT05444153
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT05443191
- Locations
- 🇫🇮
Aava Lääkärikeskus - Aava Kamppi, Annankatu 32, 00100 Helsinki, Finland, Helsinki,, Finland
🇫🇮Master Centre for Finland, Helsinki, Finland, Finland
🇫🇷Master centre for France_Paris La défense cedex, Paris, La Défense, France
A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 99
- Registration Number
- NCT05442047
- Locations
- 🇩🇪
Universitatsklinikum Würzburg - Zentrum für Herzinsuffizienz, Würzburg, Germany
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Cedars-Sinai Medical Center_Los Angeles, Beverly Hills, California, United States
INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT05438186
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together
- Conditions
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT05435677
- Locations
- 🇨🇳
Peking University Third Hospital, Northern branch, Beijing, Beijing, China
A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 152
- Registration Number
- NCT05429593
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Brandenburg, Germany
🇩🇪Parexel International GmbH, Berlin, Germany
Awareness, Care & Treatment In Obesity Management - An Observation in Mainland China
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 8000
- Registration Number
- NCT05428501
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, China